Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase III trial of bortezomib-based induction and lenalidomide consolidation/maintenance in newly diagnosed multiple myeloma
2010-019173-16Phase 3Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Feb 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of bortezomib and lenalidomide in multiple myeloma (MM) (2 arms), sponsored by Heidelberg University Hospital. Primary endpoint: Response rate (VGPR or better). Started Feb 2010; status: completed.
02
Drugs
bortezomiblenalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2010-019173-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019173-16.